Abstract

Pancreatic cancer is one of the most aggressive human tumors in the United States. Curcumin, a polyphenol derived from the Curcuma longa plant, has been reported to exert its antitumor activity in pancreatic cancer. However, the molecular mechanisms of curcumin-mediated tumor suppressive function have not been fully elucidated. In the current study, we explore whether curcumin exhibits its anti-cancer function through inhibition of oncoprotein cell division cycle 20 (Cdc20) in pancreatic cancer cells. We found that curcumin inhibited cell growth, enhanced apoptosis, induced cell cycle arrest and retarded cell invasion in pancreatic cancer cells. Moreover, we observed that curcumin significantly inhibited the expression of Cdc20 in pancreatic cancer cells. Furthermore, our results demonstrated that overexpression of Cdc20 enhanced cell proliferation and invasion, and abrogated the cytotoxic effects induced by curcumin in pancreatic cancer cells. Consistently, downregulation of Cdc20 promoted curcumin-mediated anti-tumor activity. Therefore, our findings indicated that inhibition of Cdc20 by curcumin could be useful for the treatment of pancreatic cancer patients.

Highlights

  • Pancreatic cancer (PC) is one of the most highly aggressive malignancies in humans

  • We found that curcumin inhibited the cell division cycle 20 (Cdc20) expression, leading to anti-cancer activity in pancreatic cancer (PC) cells

  • We found that downregulation of Cdc20 retarded combination of curcumin treatment led to inhibition of cell invasion to a greater degree compared invasion in both PC cell lines (Figure 6A)

Read more

Summary

Introduction

Pancreatic cancer (PC) is one of the most highly aggressive malignancies in humans. According to the American Cancer Society, there will be 53,670 estimated new cases and 43,090 deaths due to PC in the United States in 2017 [1]. The routine treatments include surgery, radiation and chemotherapy. Multiple-treatment approaches have been improved, the outcomes of PC patients are still poor. Because PC patients are diagnosed at a late stage and exhibit acquired drug resistance during chemotherapeutic treatment, the 5-year relative survival of PC is currently 7% [1]. It is essential to find new agents to improve the treatment outcome in patients with PC

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call